Previous 10 | Next 10 |
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at two upcoming investor conferences, including: Jefferies 2022 London Healthcare Conference in London, England on Wednesday, November 16 th , at 10:20 a.m. GMT (5:20 a.m. ET); and ...
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts will present 23 scientific posters, both independently and collaboratively with clients, at Neuroscience 2022, the annual meeting of the Society for Neuroscien...
Charles River Laboratories ( NYSE: CRL ) has expanded its cell therapy contract development and manufacturing facility in Memphis, Tenn. The company has added nine processing suites to the existing 16. The facility allows for the manufacture of clinical and co...
Memphis CDMO facility sets the bar for clinical- and commercial-scale cell therapy production Charles River Laboratories International, Inc. (NYSE: CRL) today announced the expansion of its cell therapy contract development and manufacturing (CDMO) facility in Memphis, Tenn....
Charles River Laboratories International, Inc. (CRL) Q3 2022 Earnings Conference Call November 2, 2022 09:00 AM ET Company Participants Todd Spencer - VP, IR James Foster - Chairman, President & CEO Flavia Pease - Corporate EVP & CFO Conference Call...
The following slide deck was published by Charles River Laboratories International, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Charles River Laboratories International, Inc. 2022 Q3 - Results - Earnings Call Presentation
Shares of Charles River Laboratories International (NYSE: CRL) are jumping today, up by 8.2% as of 11:43 a.m. ET. The solid gain came after the company announced its third-quarter results before the market opened. Charles River reported Q3 revenue of $989.2 million, up 10.4% yea...
Charles River Laboratories ( NYSE: CRL ) is trading 8.4% higher the company posted better-than expected Q3 result and raised the lower end of its profit guidance, helped by strong performance in its Discovery and Safety Assessment unit. The company now expec...
Charles River Laboratories press release ( NYSE: CRL ): Q3 Non-GAAP EPS of $2.63 beats by $0.13 . Revenue of $989.2M (+10.4% Y/Y) beats by $18.77M . Narrows 2022 Revenue Growth and Earnings Per Share Guidance Revenue growth of 10%-11% from prior view...
– Third-Quarter Revenue of $989.2 Million – – Third-Quarter GAAP Earnings per Share of $1.88 and Non-GAAP Earnings per Share of $2.63 – – Narrows 2022 Revenue Growth and Earnings Per Share Guidance – – Announces ...
News, Short Squeeze, Breakout and More Instantly...
Charles River Laboratories International Inc. Company Name:
CRL Stock Symbol:
NYSE Market:
Charles River Laboratories International Inc. Website:
Clinical trials for AAV9 gene therapy bolstered with plasmid and viral vector CDMO expertise Charles River Laboratories International, Inc. (NYSE: CRL) announced today a collaboration with the FOXG1 Research Foundation (FRF) highlighting the patient advocacy group’s model t...
Agreement establishes Charles River as the preferred partner for Autobahn Labs, leveraging drug discovery and development capabilities to accelerate the translation of academic discoveries into novel therapeutics Under the agreement, Charles River will make an equity investment in Aut...
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2024 financial results on Wednesday, August 7 th , before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 7 th , at 9:00 a.m. ET. Investors wi...